NCT07292714

A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate Efficacy and Safety of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 360 (estimated)
• Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study is a Phase II, multicenter, double-blind, randomized, parallel, placebo-controlled clinical trial designed to evaluate the efficacy, safety of 9MW1911 in patients with Chronic Obstructive Pulmonary Disease (COPD).

Conditions

• Chronic Obstructive Pulmonary Disease COPD

Interventions

Type	Name	Description
DRUG	9MW1911	Participants will receive IV 9MW1911 in each dose every 28 days.
DRUG	Phase II placebo	Participants will receive IV placebo every 28 days.

Timeline

• Start date: 2025-07-15
• Primary completion: 2027-12-01
• Completion: 2028-02-01
• First posted: 2025-12-18
• Last updated: 2025-12-18

Locations

51 sites across 1 country: China